Search

Displaying results 2301 - 2310 of 8196 in total
  1. Drug

    Microsporum canis

    go.drugbank.com/drugs/DB10843
    Approved

    Microsporum canis is a fungus which can provoke allergic reactions. Microsporum canis extract is used in allergenic testing.

  2. Drug

    Sporisorium cruentum

    go.drugbank.com/drugs/DB10873
    Approved

    Sporisorium cruentum is a fungus which can provoke allergic reactions. Sporisorium cruentum extract is used in allergenic testing.

  3. Drug

    Trichophyton rubrum

    go.drugbank.com/drugs/DB10915
    Approved

    Trichophyton rubrum is a fungus which can provoke allergic reactions. Trichophyton rubrum extract is used in allergenic testing.

  4. Drug

    Cochliobolus lunatus

    go.drugbank.com/drugs/DB10933
    Approved

    Cochliobolus lunatus is a fungus which can provoke allergic reactions. Cochliobolus lunatus extract is used in allergenic testing.

  5. Drug

    Haematonectria haematococca

    go.drugbank.com/drugs/DB10934
    Approved

    Haematonectria haematococca is a fungus which can provoke allergic reactions. Haematonectria haematococca extract is used in allergenic testing.

  6. Drug

    Neurospora sitophila

    go.drugbank.com/drugs/DB10969
    Approved

    Neurospora sitophila is a fungus which can provoke allergic reactions. Neurospora sitophila extract is used in allergenic testing.

  7. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  8. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Enfuvirtide

    go.drugbank.com/drugs/DB00109
    ApprovedInvestigational

    Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates